This document announces the issuance of US Patent 12595285B2 to Dana-Farber Cancer Institute, covering compositions and methods involving immunogenic cells expressing LMP1 (Latent Membrane Protein 1) for cancer treatment and activating T cells. The patent grants exclusive intellectual property rights to this cancer immunotherapy technology in the United States.

Affected parties including pharmaceutical companies, cancer research institutions, and biotechnology firms developing LMP1-based or related immunotherapy treatments should conduct freedom-to-operate analyses to ensure their research and product development activities do not infringe on the newly granted patent claims. This patent may impact licensing negotiations and collaborative research arrangements involving LMP1 technology.